Added benefit of ingenol mebutate is not proven

Manufacturer's dossier did not contain any relevant data for the comparison with diclofenac/hyaluronic acid gel

2013-06-06

(Press-News.org) The drug ingenol mebutate (trade name: Picato) has been approved in Germany since November 2012 as a gel for the treatment of certain forms of actinic keratosis in adults. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over diclofenac/hyaluronic acid gel. Such an added benefit cannot be derived from the dossier, however, as the drug manufacturer did not submit any relevant data: it did not cite any studies that directly compared ingenol mebutate with diclofenac/hyaluronic acid gel, and the method chosen by the manufacturer for an indirect comparison was unsuitable.

G-BA specified appropriate comparator therapy

Ingenol mebutate is approved for the treatment of flat, non-callous skin lesions. These are called non-hyperkeratotic and non-hypertrophic actinic keratoses. This disease can develop into a form of skin cancer (squamous cell carcinoma). The Federal Joint Committee (G-BA) specified diclofenac/hyaluronic acid gel as appropriate comparator therapy.

No direct comparative studies available

In its dossier, the manufacturer did not cite any randomized controlled trials (RCTs) that directly compared ingenol mebutate gel with diclofenac/hyaluronic acid gel. It therefore aimed for an indirect comparison. However, in the opinion of the manufacturer it was not possible to use a procedure appropriate for this, namely an adjusted indirect comparison with a common point of reference (intermediate comparator). It stated that the substances called vehicle gels that ingenol mebutate and diclofenac/hyaluronic acid were compared with in the available studies might differ in efficacy, and are therefore not comparable. These substances could therefore not be used as intermediate comparator.

Method of analysis unsuitable for indirect comparison

Instead, the pharmaceutical company used a method it called "chaining of direct comparisons". In such a comparison across several comparators it is indispensable, however, that direct comparisons exist for each link in the chain, i.e. for each pair of comparators. This condition was not fulfilled, however, as the manufacturer presented a non-adjusted comparison for one link in the chain. Hence the method of analysis was unsuitable, and its results could therefore not be used. An added benefit of ingenol mebutate is therefore not proven.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.

### An overview of the results of IQWiG's benefit assessment is given by a German-language executive summary. In addition, the website gesundheitsinformation.de, published by IQWiG, provides easily understandable and brief German-language information on ingenol mebutate.

The G-BA website contains both general English-language information on benefit assessment pursuant to §35a Social Code Book V and specific German-language information on the assessment of ingenol mebutate.

ELSE PRESS RELEASES FROM THIS DATE:

Molecular VELCRO for chromosome stability

2013-06-06

The genome is full of sequence repetitions. Sequence motif is added after sequence motif, sometimes more than a hundred times. Erratically it seems. And these sequence motifs bind proteins that control transcription factors in regions of the genome where no transcription should occur. A conundrum. Nicolas Thomä, group leader at the Friedrich Miescher Institute for Biomedical Research, and his team together with the team of David Shore at the University of Geneva, have now been able to give an answer and assign a function to this seeming inconsistency. In a study published ...

Added benefit of dapagliflozin is not proven

2013-06-06

Dapagliflozin (trade name: Forxiga) has been approved in Germany since November 2012 for the treatment of type 2 diabetes mellitus. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG) the German Institute for Quality and Efficiency in Health Care (IQWiG) examined whether this new drug offers an added benefit over the current standard therapy. No such added benefit can be derived from the dossier, however, because the drug manufacturer did not present any relevant data for any of the possible therapeutic indications ...

Big game hunting in Spain has increased in the last 30 years

2013-06-06

Since ancient times, the pressures of excessive hunting have contributed to the gradual decline of wildlife populations and even the extinction of certain species in many areas. Researchers from the Polytechnic University of Madrid (UPM) and the Centre for Forestry Research (INIA-CIFOR) have studied the developments in big game in Spain between 1972 and 2007 to gain an understanding of the hunting trends of the last decades. "We have analysed the general trends in official statistics on hunters, hunting weapons, hunting grounds and captures. Our main conclusion is that ...

Spain receives ever more solar radiation

2013-06-06

Solar radiation in Spain has increased by 2.3% every decade since the 1980s, according to a study by researchers from the University of Girona and the Federal Institute of Technology (ETH) in Zurich. This increase is linked to the decreased presence of clouds, which has increased the amount of direct radiation reaching us from the Sun. "The mean annual G series over Spain shows a tendency to increase during the 1985-2010 period, with a significant linear trend of + 3.9 W m-2 [2.3% more] per decade." This is the main conclusion of a study published in the magazine 'Global ...

Alpine lakes reflect climate change

2013-06-06

Increases in temperature as a result of climate change are mirrored in lake waters where temperatures are also on the rise. A new study, by Dr. Martin Dokulil, retired researcher from the Institute for Limnology at the University of Innsbruck in Austria, forecasts surface water temperatures in large Austrian lakes for 2050 and discusses the impact on the lakes' structure, function and water quality. The research is published online in Springer's journal Hydrobiologia. Austria has a multitude of lakes varying widely in type, size, flushing, altitude and geographic location. ...

Study suggests second life for possible spintronic materials

2013-06-06

ATHENS, Ohio (June 6, 2013) – Ten years ago, scientists were convinced that a combination of manganese and gallium nitride could be a key material to create spintronics, the next generation of electronic devices that operate on properties found at the nanoscale. But researchers grew discouraged when experiments indicated that the two materials were as harmonious as oil and water. A new study led by Ohio University physicists suggests that scientists should take another look at this materials duo, which once was heralded for its potential to be the building block for devices ...

Quantum teleportation between atomic systems over long distances

2013-06-06

Researchers have been able to teleport information from light to light at a quantum level for several years. In 2006, researchers at the Niels Bohr Institute succeeded in teleporting between light and gas atoms. Now the research group has succeeded in teleporting information between two clouds of gas atoms and to carry out the teleportation – not just one or a few times, but successfully every single time. The results are published in the scientific journal, Nature Physics. "It is a very important step for quantum information research to have achieved such stable results ...

Readily-available drugs may reduce devastating symptoms of Tay-Sachs disease: Study

2013-06-06

A team of researchers has made a significant discovery which may have a dramatic impact on children stricken with Tay-Sachs disease, a degenerative and fatal neurological condition that often strikes in the early months of life. Available drugs may dramatically ease a child's suffering, say scientists. "There is hope for this disease," says Suleiman Igdoura, lead researcher of the study and an associate professor of biology at McMaster University. "Imagine what that could mean for parents who have a child diagnosed with this incurable condition, who may have only ...

Research unveils insight into a debilitating brain disease

2013-06-06

Athens, Ga. – From the neurons that enable thought to the keratinocytes that make toenails grow–a complex canopy of sugar molecules, commonly known as glycans, envelop every living cell in the human body. These complex carbohydrate chains perform a host of vital functions, providing the necessary machinery for cells to communicate, replicate and survive. It stands to reason, then, that when something goes wrong with a person's glycans, something goes wrong with them. Now, researchers at the University of Georgia are learning how changes in normal glycan behavior are ...

Vitamin D deficiency may help spread of hepatitis B throughout liver

2013-06-06

Researchers from Germany have found that low levels of vitamin D are associated with high levels of hepatitis B virus (HBV) replication. Findings published online in Hepatology, a journal of the American Association for the Study of Liver Diseases, suggest seasonal fluctuations in vitamin D and HBV levels point to a link in these variables among patients with chronic HBV. While highly effective vaccines are available, HBV still remains one of the most significant infectious diseases worldwide. In fact, the World Health Organization (WHO) states that HBV is 50 to 100 ...

Added benefit of ingenol mebutate is not proven

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: